Join the Pembrolizumab group to help and get support from people like you.
Pembrolizumab News (Page 4)
FDA Medwatch Alert: Keytruda (pembrolizumab) in Patients with Multiple Myeloma: FDA Statement - Two Clinical Trials on Hold
ISSUE: Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology...
FDA Approves Keytruda (pembrolizumab) as First Cancer Treatment for any Solid Tumor with a Specific Genetic Feature
May 23, 2017 – The U.S. Food and Drug Administration today granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker). This is the first time...
FDA Approves Merck’s Keytruda (pembrolizumab) for Classical Hodgkin Lymphoma (cHL)
KENILWORTH, N.J. March 14, 2017 --(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Merck’s Keytruda (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer
KENILWORTH, N.J.--(BUSINESS WIRE) October 24, 2016 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Merck’s Keytruda (pembrolizumab) for Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
KENILWORTH, N.J.--(BUSINESS WIRE)--August 5, 2016 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Expanded Indication for Keytruda (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
KENILWORTH, N.J.--(BUSINESS WIRE) December 18, 2015 --Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has...
FDA Approves Keytruda (pembrolizumab) for Advanced Non-Small Cell Lung Cancer
October 2, 2015 – The U.S. Food and Drug Administration today granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non-small cell lung cancer...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Breast Cancer, Renal Cell Carcinoma, Ovarian Cancer, Non-Small Cell Lung Cancer, Melanoma, Hepatocellular Carcinoma, Gastric Cancer, Endometrial Cancer, Colorectal Cancer